IFCC and ISOBM Working Group on Tumor Marker Harmonization
Invitation to participate – Global survey on tumour marker testing practices
The IFCC and ISOBM Working Group on Tumour Marker Harmonization is currently investigating opportunities to improve the harmonization of tumour marker testing, with a particular focus on carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA 15-3).
While full technical harmonization of patient results across platforms remains a challenge, we believe that standardized reporting—particularly clear identification of the test or measurement procedure used—plays an important role in ensuring appropriate interpretation and use of tumor marker results.
To better understand current global practices, they are conducting a brief survey targeting clinical laboratories worldwide. The questionnaire addresses routine practices in tumour marker use and reporting, and also includes specific questions related to PSA testing.
The goal is to evaluate current practices, identify challenges faced by laboratories, and potentially develop guidance to support best practices in this area. They would be grateful if you, or a colleague responsible for tumour marker testing, could complete the survey available at the following link: